Rene Pretorius

Another GLP-1 Drug Access Model: Will a Co-Pay Cap Revolutionize Affordability?
The Impact of MFN Pricing on the U.S. Biosimilar Market
MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alig...
EMA AI Tool Qualification: How the AIM-NASH Approval Sets a Roadmap for Medic...
A System Dynamics Approach to Lowering Drug Prices by 30–80% in the US
Revolutionizing Hepatitis C Treatment: The Transformative Role of Direct-Acti...